Amphastar Pharmaceuticals (AMPH) Long-Term Deferred Tax (2013 - 2026)

Amphastar Pharmaceuticals has reported Long-Term Deferred Tax for 14 years, with the latest figure at $42.5 million in Q2 2026.

• On a quarterly basis, Long-Term Deferred Tax fell 40.3% year-over-year to $42.5 million in Q2 2026; TTM through Jun 2026 was $42.5 million, a 40.3% decrease from a year earlier, with the FY2025 full-year figure at $42.5 million, down 40.3% from the prior year.
• Long-Term Deferred Tax was $42.5 million for Q2 2026 at Amphastar Pharmaceuticals, roughly flat from $42.5 million in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $71.1 million in Q4 2024, with the low at $22.4 million in Q1 2022.
• Average Long-Term Deferred Tax over 5 years is $47.3 million, with a median of $42.5 million recorded in 2025.
• The sharpest annual moves came in 2023 and 2025: Long-Term Deferred Tax surged 82.45% in 2023, then tumbled 40.3% in 2025.
• Over 5 years, Long-Term Deferred Tax stood at $38.5 million in 2022, then soared by 38.22% to $53.3 million in 2023, then surged by 33.56% to $71.1 million in 2024, then tumbled by 40.3% to $42.5 million in 2025, then changed by 0.0% to $42.5 million in 2026.
• The last three Long-Term Deferred Tax figures came in at $42.5 million (Q2 2026), $42.5 million (Q1 2026), and $42.5 million (Q4 2025), per Business Quant data.